Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $26.64 Analyst target: $30.21 Upside: 13.40%
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
See the full interactive analysis & chart →Informational only — not investment advice.